Apixaban drug utilization study in Stroke prevention in atrial fibrillation (SPAF)

Study identification

• PURI:
  https://redirect.ema.europa.eu/resource/28119
• EU PAS number:
  EUPAS13180
• Study ID:
  28119
• Official title and acronym:
  Apixaban drug utilization study in Stroke prevention in atrial fibrillation (SPAF)
• DARWIN EU® study:
  No
• Study countries:
  Spain
• Study status:
  Finalised

Research institution and networks

Institutions

Fundació Institut Universitari per a la Recerca a l'Atenció Primària de Salut Jordi Gol i Gurina, IDIAPJGol

Spain

Study timelines

Date when funding contract was signed

Planned: 11/11/2015

Actual: 11/11/2015

Study start date

Planned: 29/04/2016

Actual: 01/06/2016

Data analysis start date

Planned: 01/07/2016

Actual: 05/07/2016

Date of interim report, if expected

Planned: 01/11/2016

Actual: 30/11/2016

Date of final study report

Planned: 30/12/2016

Actual: 08/03/2017

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Pfizer

Study protocol

Initial protocol

Apixaban B0661076 15-Feb

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable